Alexion Pharmaceuticals, Inc.
METHODS OF TREATING NEUROFIBROMATOSIS TYPE 1 AND RELATED CONDITIONS WITH ALKALINE PHOSPHATASE
Last updated:
Abstract:
The disclosure features methods for treating at least one symptom of neurofibromatosis type 1, treating at least one symptom of dystrophic scoliosis, or inducing bone healing by administering a soluble alkaline phosphatase (sALP) to the patient.
Status:
Application
Type:
Utility
Filling date:
9 Aug 2019
Issue date:
3 Jun 2021